Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Crixivan i kombination med antiretrovirale nukleosidanaloger til behandling af hiv- inficerede voksne, unge og børn over fire år opvejer risiciene.
The Committee for Medicinal Products for Human Use (CHMP) decided that Crixivan’ s benefits are greater than its risks in combination with antiretroviral nucleoside analogues for the treatment of HIV-1 infected adults, adolescents, and children four years of age and older.